The direct thrombin inhibitors

their role and use for rational anticoagulation.

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Major clinical advantages are achieved when direct thrombin inhibitors are used in venous thromboembolism. These agents provide more reliable anticoagulant response patterns because they are not significantly bound to plasma proteins and few, if any, drug-drug interactions are seen. The studies to date confirm that not all direct thrombin inhibitors are the same. The new reversible, short-acting catalytic site-specific drugs provide an excellent safety profile and high degree of efficacy for the prophylaxis and treatment of venous thromboembolism and pulmonary embolic states. The availability of the oral prodrug ximelagatran allows reproducible, effective, and safe direct thrombin inhibition without the requirement for coagulation laboratory monitoring; it appears destined to be the oral anticoagulant of the future.

Original languageEnglish (US)
JournalHematology/Oncology Clinics of North America
Volume19
Issue number1
StatePublished - Feb 2005

Fingerprint

Antithrombins
Venous Thromboembolism
Anticoagulants
Prodrugs
Drug Interactions
Thrombin
Pharmaceutical Preparations
Blood Proteins
Catalytic Domain
Safety
Lung
ximelagatran

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

@article{60b782ac264842d4b2cd529ca0d62594,
title = "The direct thrombin inhibitors: their role and use for rational anticoagulation.",
abstract = "Major clinical advantages are achieved when direct thrombin inhibitors are used in venous thromboembolism. These agents provide more reliable anticoagulant response patterns because they are not significantly bound to plasma proteins and few, if any, drug-drug interactions are seen. The studies to date confirm that not all direct thrombin inhibitors are the same. The new reversible, short-acting catalytic site-specific drugs provide an excellent safety profile and high degree of efficacy for the prophylaxis and treatment of venous thromboembolism and pulmonary embolic states. The availability of the oral prodrug ximelagatran allows reproducible, effective, and safe direct thrombin inhibition without the requirement for coagulation laboratory monitoring; it appears destined to be the oral anticoagulant of the future.",
author = "Frenkel, {Eugene P.} and Shen, {Yu Min} and Haley, {Barbara B.}",
year = "2005",
month = "2",
language = "English (US)",
volume = "19",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - The direct thrombin inhibitors

T2 - their role and use for rational anticoagulation.

AU - Frenkel, Eugene P.

AU - Shen, Yu Min

AU - Haley, Barbara B.

PY - 2005/2

Y1 - 2005/2

N2 - Major clinical advantages are achieved when direct thrombin inhibitors are used in venous thromboembolism. These agents provide more reliable anticoagulant response patterns because they are not significantly bound to plasma proteins and few, if any, drug-drug interactions are seen. The studies to date confirm that not all direct thrombin inhibitors are the same. The new reversible, short-acting catalytic site-specific drugs provide an excellent safety profile and high degree of efficacy for the prophylaxis and treatment of venous thromboembolism and pulmonary embolic states. The availability of the oral prodrug ximelagatran allows reproducible, effective, and safe direct thrombin inhibition without the requirement for coagulation laboratory monitoring; it appears destined to be the oral anticoagulant of the future.

AB - Major clinical advantages are achieved when direct thrombin inhibitors are used in venous thromboembolism. These agents provide more reliable anticoagulant response patterns because they are not significantly bound to plasma proteins and few, if any, drug-drug interactions are seen. The studies to date confirm that not all direct thrombin inhibitors are the same. The new reversible, short-acting catalytic site-specific drugs provide an excellent safety profile and high degree of efficacy for the prophylaxis and treatment of venous thromboembolism and pulmonary embolic states. The availability of the oral prodrug ximelagatran allows reproducible, effective, and safe direct thrombin inhibition without the requirement for coagulation laboratory monitoring; it appears destined to be the oral anticoagulant of the future.

UR - http://www.scopus.com/inward/record.url?scp=15544379843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15544379843&partnerID=8YFLogxK

M3 - Article

VL - 19

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 1

ER -